Tetsuya Mishima
Direttore/Membro del Consiglio presso Anaeropharma Science, Inc.
Profilo
Tetsuya Mishima is currently the Representative Director at Anaeropharma Science, Inc. He previously held positions as Director at CellGenTech, Inc. and Partner at Watervein Partners KK.
Prior to his current and former positions, he worked as a Principal at Bank of America Corp.
Mishima received his undergraduate and graduate degrees from Tokyo Institute of Technology.
Posizioni attive di Tetsuya Mishima
| Società | Posizione | Inizio |
|---|---|---|
Anaeropharma Science, Inc.
 Anaeropharma Science, Inc. BiotechnologyHealth Technology Anaeropharma Science, Inc. operates as a holding company that engages in the research and development of therapeutics to target hypoxic environment in solid cancers. It develops bifidobacterium technologies to create anti-cancer drugs. The firm's bifidobacterium therapeutics accumulates to the solid tumor when intravenously injected. The company was founded by Minoru Fujimori and Shunichiro Taniguchi on August 9, 2004 and is headquartered in Tokyo, Japan. | Direttore/Membro del Consiglio | - |
Watervein Partners KK
 Watervein Partners KK Investment ManagersFinance Watervein Partners KK (Watervein Partners) is an independent venture capital firm headquartered in Tokyo, Japan. The firm was founded in 2002 by Kuroishi Masafumi. | Investitore di Private Equity | 01/09/2002 |
CellGenTech, Inc.
 CellGenTech, Inc. Pharmaceuticals: MajorHealth Technology CellGenTech, Inc. engages in the research and development of drugs for new gene therapy and regenerative medicine. It offers adipocyte-based medicine, technology for the development of gene/cell therapies. It also provides protein supplemental therapy solutions in the areas of hereditary diseases; orphan diseases; intractable diseases, such as lysosome and hemophilia; diabetics; arteriosclerotic diseases, and cancer or degenerative neuropathies. The company was founded by Masayuki Aso on October 20, 2003 and is headquartered in Chiba, Japan. | Direttore/Membro del Consiglio | 01/01/2005 |
Precedenti posizioni note di Tetsuya Mishima
| Società | Posizione | Fine |
|---|---|---|
| BANK OF AMERICA CORPORATION | Corporate Officer/Principal | - |
Formazione di Tetsuya Mishima
| Tokyo Institute of Technology | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| BANK OF AMERICA CORPORATION | Finance |
| Aziende private | 3 |
|---|---|
Anaeropharma Science, Inc.
Anaeropharma Science, Inc. BiotechnologyHealth Technology Anaeropharma Science, Inc. operates as a holding company that engages in the research and development of therapeutics to target hypoxic environment in solid cancers. It develops bifidobacterium technologies to create anti-cancer drugs. The firm's bifidobacterium therapeutics accumulates to the solid tumor when intravenously injected. The company was founded by Minoru Fujimori and Shunichiro Taniguchi on August 9, 2004 and is headquartered in Tokyo, Japan. | Health Technology |
Watervein Partners KK
Watervein Partners KK Investment ManagersFinance Watervein Partners KK (Watervein Partners) is an independent venture capital firm headquartered in Tokyo, Japan. The firm was founded in 2002 by Kuroishi Masafumi. | Finance |
CellGenTech, Inc.
CellGenTech, Inc. Pharmaceuticals: MajorHealth Technology CellGenTech, Inc. engages in the research and development of drugs for new gene therapy and regenerative medicine. It offers adipocyte-based medicine, technology for the development of gene/cell therapies. It also provides protein supplemental therapy solutions in the areas of hereditary diseases; orphan diseases; intractable diseases, such as lysosome and hemophilia; diabetics; arteriosclerotic diseases, and cancer or degenerative neuropathies. The company was founded by Masayuki Aso on October 20, 2003 and is headquartered in Chiba, Japan. | Health Technology |
- Borsa valori
- Insiders
- Tetsuya Mishima
